Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities by Brisse, Ellen et al.
Advances in the pathogenesis of primary and secondary
haemophagocytic lymphohistiocytosis: differences and
similarities
Ellen Brisse,1 Carine H. Wouters2,* and Patrick Matthys1,*
1Laboratory of Immunobiology, Rega Institute, KU Leuven, Leuven, Belgium and 2Laboratory of Paediatric Immunology, KU Leuven,
University Hospital Gasthuisberg, Leuven, Belgium
Summary
Haemophagocytic lymphohistiocytosis (HLH) comprises a
heterogeneous spectrum of hyperinflammatory conditions
that are inherited (primary HLH) or acquired in a context of
infections, malignancies or autoimmune/autoinflammatory
disorders (secondary HLH). Genetic defects in the cytotoxic
machinery of natural killer and CD8+ T cells underlie pri-
mary HLH, with residual cytotoxicity determining disease
severity. Improved sequencing techniques have expanded the
range of causal mutations and have redefined many cases of
secondary HLH as primary HLH and vice versa, blurring the
distinction between both subtypes. These insights allow HLH
to be conceptualized as a threshold disease, in which inter-
play between various genetic and environmental factors
causes progressive inflammation into a critical point, beyond
which uncontrolled activation of immune cells and excessive
cytokine production give rise to the cardinal symptoms of
HLH. Various pathogenic pathways may thus converge to a
common end stage of fulminant HLH.
Keywords: Haemophagocytic syndrome, haemophagocytic
lymphohistiocytosis, macrophage activation syndrome,
pathogenesis, genetics.
Haemophagocytic lymphohistiocytosis (HLH) is a rare, life-
threatening syndrome caused by uncontrolled activation of
lymphocytes and macrophages. Characteristic symptoms are
presented in Table I. A genetic and an acquired form, termed
primary and secondary HLH, are distinguished. The former
is caused by mutations in genes regulating granule-dependent
cytotoxicity of natural killer (NK) cells and cytotoxic T lym-
phocytes (CTLs), the latter presents without a familial history
as a complication of various conditions (Janka & Lehmberg,
2014).
Primary HLH
Primary HLH is inherited in an autosomal recessive or X-
linked manner. Mutations in nine genes have been associated
with HLH so far. The encoded proteins play non-redundant
roles in granule effector protein synthesis or in the forma-
tion, trafficking, docking, priming and membrane fusion of
cytotoxic granules (Usmani et al, 2013). Primary HLH
patients with a diverse genetic background therefore share a
common immunophenotype of decreased to absent cytotoxi-
city.
Based on the underlying mutations, five types of familial
HLH (FHL-1 to FHL-5) and four immunodeficiency syn-
dromes closely related to HLH are distinguished.
Familial HLH type 1-5
Mutations in PRF1, coding for the granule effector protein
perforin (PRF1), were the first to be causally linked to pri-
mary HLH (Stepp et al, 1999). Today, 30–40% of molecu-
larly diagnosed patients possesses a mutation in PRF1,
classifying them as FHL-2 (Cetica et al, 2016). Upon degran-
ulation of CTLs or NK cells, perforin monomers are released
into the immune synapse, where they polymerize in the tar-
get cell membrane to form pores, through which granzymes
enter to induce apoptosis (Sieni et al, 2014; de Saint Basile
et al, 2015).
Mutations in UNC13D are associated with FHL-3, affect-
ing one-third of patients with primary HLH. UNC13D
encodes Munc13-4, also termed UNC13D, which plays a
non-redundant role in the priming of docked cytolytic gran-
ules, preparing the granules for membrane fusion. Munc13-4
does so by regulating the interaction between vesicle-SNARE
(soluble N-ethyl-maleimide-sensitive-factor attachment pro-
tein receptor) and target (t)-SNARE proteins, required to
form a SNARE complex enabling membrane fusion of cyto-
toxic vesicles. In addition to cytotoxicity, UNC13D mutations
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affect platelet granule exocytosis and neutrophil phagosome
maturation, thus contributing to coagulopathy and impaired
intracellular bacterial killing (Janka & Lehmberg, 2014; Naka-
mura et al, 2015).
FHL-4 accounts for as few as 5% of FHL cases. It results
from defects in syntaxin-11, a t–SNARE protein encoded by
STX11, which regulates granule membrane fusion. The defect
not only reduces the cytotoxic function of CTLs and NK cell,
but also impairs neutrophil and platelet granule exocytosis,
similar to FHL-3 (D’Orlando et al, 2013; Tang, 2015). Silenc-
ing of syntaxin-11 in human macrophages in vitro was found
to increase engulfment of apoptotic and opsonized target
cells, indicating a negative regulatory role for STX11 in
haemophagocytosis (Zhang et al, 2008b).
FHL-5, representing 5–20% of FHL cases, is caused by
mutations in STXBP2, encoding Munc18-2, also termed syn-
taxin binding protein 2 (STXBP2) (de Saint Basile et al,
2015; Cetica et al, 2016). Munc18-2 interacts with syntaxin-
11, together facilitating formation of the SNARE complex.
Accordingly, deficiencies in Munc18-2 and syntaxin-11 result
in similarly defective cytotoxicity. Interestingly, cytotoxic
function in both FHL-4 and FHL-5 can be restored by inter-
leukin 2 (IL2) stimulation, which enhances the levels of syn-
taxin-3 and Munc18-1, substituting for defective syntaxin-11
and Munc18-2, respectively (Hackmann et al, 2013).
Nonetheless, the clinical presentation of FHL-5 differs from
that of other FHL subtypes (Pagel et al, 2012), which is
probably related to additional functions of STXBP2.
Munc18-2 is involved in several degranulation processes,
including platelet granule secretion, mast cell degranulation
and neutrophil granule mobilization (Kostova et al, 2015).
Many FHL-5 patients present with severe enteropathy, which
results from defective Munc18-2 expression in intestinal and
renal epithelium, causing membrane trafficking malfunction
in gut and kidneys (Stepensky et al, 2013). Given that ery-
throcytes also express Munc18-2, FHL-5 patients possess an
intrinsic erythroid defect, characterized by aberrant erythro-
poiesis, erythrocyte maturation and cell morphology, possibly
contributing to anaemia (Kostova et al, 2015).
In the remaining 8–10% of FHL cases, suspected on the
basis of familial history, parental consanguinity, or confirmed
immunological deficiencies, the underlying molecular defects
are yet to be determined (de Saint Basile et al, 2015; Cetica
et al, 2016). This subgroup includes patients with FHL-1, in
which the causative mutation is located on chromosome 9
(9q21.1). The causal gene and corresponding protein have
not yet been identified (Ohadi et al, 1999).
Primary immunodeficiency syndromes associated with
HLH
Griscelli syndrome type 2, Chediak–Higashi syndrome and Her-
mansky-Pudlak syndrome type 2. Griscelli syndrome type 2
(GS2), Chediak–Higashi syndrome (CHS) and Hermansky-
Pudlak syndrome type 2 (HPS2) present with overall defects
in the trafficking and exocytosis of secretory lysosomes.
Given that lysosomes exert important functions in multiple
cell types, including neurons, melanocytes, platelets, granulo-
cytes, T and NK cells, these defects can result in progressive
neurological disease, impaired pigmentation, compromised
platelet clotting, neutropenia, decreased granulocyte function
and defective cytotoxicity (Dotta et al, 2013). As the muta-
tions underlying FHL-3, -4 and -5 also affect exocytosis pro-
cesses other than cytolytic degranulation, including platelet
and neutrophil secretions, the traditional distinction between
FHL and the immunodeficiency syndromes associated with
HLH has become an artificial one (Janka & Lehmberg,
2014).
GS2 is linked to mutations in RAB27A, which codes for a
GTPase that directly interacts with Munc13–4. This interac-
tion is mandatory for the docking of cytotoxic granules at
the plasma membrane. RAB27A also appears to regulate the
polarized transport of granules towards the docking site
(Dotta et al, 2013; Usmani et al, 2013; Sieni et al, 2014).
Mutations in LYST are responsible for defective formation,
maturation and function of different secretory lysosomes in
CHS. LYST (lysosomal trafficking regulator) regulates protein
trafficking towards, and protein sorting in, lysosomes. Defi-
ciency results in giant intracytoplasmic lysosomes in melano-
cytes, neurons, neutrophils, monocytes, eosinophils, NK cells
and lymphocytes, possibly hampering vesicle transport along
Table I. Overview of characteristic HLH symptoms
Clinical symptoms Laboratory abnormalities
Fever Pancytopenia
Splenomegaly Thrombocytopenia
Hepatomegaly Anaemia
Lymphadenopathy Neutropenia
Liver dysfunction Lymphopenia
Bleeding diathesis Leukopenia
Oedema Hyperferritinaemia
Skin rash Hypertriglyceridaemia
Central nervous system dysfunction Hyperbilirubinaemia
Irritability, headaches, encephalopathy Elevated liver enzymes
Ataxia, seizures, coma Elevated lactate
dehydrogenaseMulti-organ failure
Hypofibrinogenaemia
Elevated D dimers
Histological features Hypoalbuminaemia
Tissue infiltration of activated
immune cells
Hypoproteinaemia
Haemophagocytosis
Hyponatraemia
Disseminated intravascular coagulation
Reduced NK cell
cytotoxicity
Reduced CTL cytotoxicity
Elevated soluble CD163
Elevated soluble CD25
Hypercytokinaemia
CTL, cytotoxic T lymphocyte; NK, natural killer.
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the microtubule cytoskeleton and obstructing exocytosis
(Dotta et al, 2013; Sieni et al, 2014).
Hermansky-Pudlak syndrome type 2 is caused by muta-
tions in AP3B1, encoding the b3A subunit of adaptor protein
3 (AP3). AP3 is part of a complex regulating recruitment
and protein sorting in lysosomes, like platelet dense granules,
melanosomes, osteoclast granules and cytotoxic granules.
Defects compromise the function of secretory lysosomes and
impair antigen presentation, NKT cell development and the
microtubule-guided movement of lysosomes towards the
immune synapse. Thus, AP3B1 mutations explain the defec-
tive cytotoxic function of CTLs and NK cells in all HPS2
patients examined to date. Nonetheless, HLH has been
described in only 2 patients so far, of which one also carried
a heterozygous RAB27A mutation (Enders et al, 2006; Jessen
et al, 2013a). Hence, the contribution of AP3B1 mutations to
HLH susceptibility requires further clarification.
X-linked lymphoproliferative disease. In X-linked lymphopro-
liferative disease (XLP), no severe defects in NK cell or CTL
cytotoxic function are present, as the causal mutations do
not directly affect the proteins involved in granule-mediated
cytotoxicity (Bryceson et al, 2012; Usmani et al, 2013).
Instead, XLP is characterized by extreme susceptibility to
Epstein-Barr virus (EBV), with the first encounter usually
provoking HLH. Patients also carry a higher risk of EBV-
associated lymphomas (Janka & Lehmberg, 2014).
Mutations causing XLP-1 have been localized to SH2D1A,
encoding signalling lymphocyte activation molecule (SLAM)-
associated protein (SAP), also termed SH2 domain-containing
1A. SAP predominantly interacts with activating receptor 2B4
on NK cells, stimulating cytotoxicity. In T and B cells it binds
to costimulatory SLAM molecules, promoting their effector
function. Hence, lack of SAP depresses NK and CTL function
and is thought to result in NKT cell deficiency as well. The
remarkable susceptibility to EBV has been explained by a selec-
tive cytotoxic impairment of SAP-deficient CTLs towards
infected B cells. In the absence of SAP, the CTL response to B-
cell-mediated antigen presentation is defective, resulting in a
failure to control EBV infection (Palendira et al, 2011; Sieni
et al, 2014; Brisse et al, 2015; de Saint Basile et al, 2015).
XLP-2 is linked to loss-of-function mutations in XIAP
(BIRC4), encoding X-linked inhibitor of apoptosis (XIAP).
As XIAP inhibits the activity of different caspases, cells of
XIAP-deficient patients show higher apoptosis rates in vitro.
Accordingly, XIAP mutations are assumed to increase lym-
phocyte susceptibility to activation-induced cell death, which
may appear paradoxical in the event of HLH, typically char-
acterized by excessive lymphocyte proliferation and activa-
tion. Since XIAP-deficient T and NK cells display apparently
normal in vitro cytotoxic functions, HLH development in
XLP-2 may be linked to other pathogenic processes, such as
accumulating apoptotic cells and persisting EBV-infected
cells, triggering excessive immune activation (Marsh et al,
2010; de Saint Basile et al, 2015). XLP-associated HLH was
previously assumed to occur only in males, however, two
HLH cases have recently been reported in female patients
carrying a heterozygous XIAP mutation that significantly
reduced XIAP expression due to highly skewed X-chromo-
some inactivation of the wild-type allele (Holle et al, 2015;
Yang et al, 2015).
Genotype/phenotype correlations in primary HLH
Advances in genetic screening have driven an on-going dis-
covery of ‘atypical’ mutations in primary HLH that are asso-
ciated with delayed onset and/or an attenuated phenotype
(Zhang et al, 2011, 2014a). These ‘atypical’ mutations have
expanded the perception of primary HLH, formerly consid-
ered a disorder restricted to babies and young infants, to
include patients of all ages.
The relationship between genotype and phenotype in pri-
mary HLH has been extensively investigated using mouse
models. Comparative studies of murine primary HLH,
induced by viral infection, revealed a range of severities that
were inversely correlated with residual cytotoxicity. Prf1/
mice, having the most profound cytotoxic impairment, dis-
played a fatal, full-blown HLH syndrome, closely followed in
severity by Rab27a/ mice. After a severe acute phase of
disease, Stx11/ mice progressed into a chronic, attenuated
stage, while souris Lyst/ mice showed a mild phenotype
from the onset of disease. HLH in Ap3b1/mice was only
transient and beige Lyst/ mice exhibited few, if any, HLH-
like symptoms (Jessen et al, 2013a,b; Sepulveda et al, 2013).
Noteworthy, both beige and souris mice represent a model
for CHS, but carry different Lyst mutations. NK cell cytotoxi-
city is equally depressed, but the beige mutation impairs CTL
function considerably less than the souris mutation, explain-
ing the lack of HLH features in beige mice and supporting
the theory of residual CTL cytotoxicity as a key determinant
of HLH development (Jessen et al, 2011).
In primary HLH patients, disease severity, as estimated by
the age of disease onset, was found to be determined by the
mutated gene and the nature of the mutation (Jessen et al,
2011, 2013b).
Classic cases of primary HLH are caused by biallelic,
recessive mutations in the coding sequence of any of the nine
aforementioned genes. In these cases, homozygous nonsense
or null mutations result in absent or barely detectable levels
of the encoded proteins, predisposing to early-onset, severe
HLH. Considering biallelic loss-of-function mutations, a gra-
dation in the age of presentation was distinguished from ear-
liest onset in FHL-2 to moderately early onset in GS2 and
FHL-3, intermediate onset in FHL-4 and generally later pre-
sentation in CHS and HPS2. The age of onset was inversely
correlated with the residual cytotoxic function of the
patients’ CTLs, reflecting the murine data (Horne et al, 2008;
Jessen et al, 2013b; Sepulveda et al, 2013).
Nonsense mutations are rare in atypical, late-onset pri-
mary HLH. Rather, ‘milder’ missense mutations are detected
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(Zhang et al, 2011; Wang et al, 2014; Tesi et al, 2015a; Cetica
et al, 2016), causing partial impairment of protein function
or decreased protein production. Additionally, mutations
may be found outside of the coding sequence, in evolution-
ary conserved noncoding regions, including splice-site muta-
tions, resulting in transcript defects, and mutations in
intronic transcription regulatory regions, disrupting tran-
scription factor binding (Pagel et al, 2012; Entesarian et al,
2013; Meeths et al, 2014; Qian et al, 2014; Zhang et al,
2014b). Deep intronic mutations are particularly abundant in
FHL-3 patients (Qian et al, 2014).
Instead of monogenic homozygous defects, monogenic
compound heterozygous mutations may predispose to late-
onset primary HLH (Zhang et al, 2011). Bigenic or polygenic
heterozygous mutations have also been reported. Additive
effects are plausible, because all FHL genes are involved in
the same cytolytic pathway. Heterozygous mutations that
each partially impair cytotoxic function may generate a ‘gene
dosage’ effect through synergy (Zhang et al, 2011, 2014a).
This was corroborated by the generation of polygenic mouse
models, in which the accumulation of heterozygous muta-
tions in Rab27a, Prf1 and/or Stx11 reduced cytotoxic func-
tion and increased the risk of developing virus-induced HLH
(Sepulveda et al, 2016). Heterozygous mutations in X-linked
genes may also cause HLH in female patients, depending on
the percentage of wild-type X-chromosome inactivation
(Holle et al, 2015; Yang et al, 2015). Moreover, monoallelic
missense mutations in STXBP2 or RAB27A have been
described to cause late-onset FHL in a (partial) dominant-
negative manner (Spessott et al, 2015; Zhang et al, 2016).
These findings stretch the traditional notion of primary HLH
as a monogenic, homozygous recessive disorder.
It was recently hypothesized that a so-called ‘second-hit’
mechanism, involving non-HLH-related mutations, could
synergize with cytotoxicity-affecting mutations to induce
late-onset primary HLH. Homozygous mutations in
PCDH18, increasing activation and reducing apoptosis of
CTLs, on top of compound heterozygous PRF1 mutations,
were reported to co-trigger FHL-2 (Gao et al, 2016).
Together, murine and patient data indicate a continuum
of primary HLH in which the genotype, i.e. affected genes
and the nature of mutations, translates into a so-called ‘im-
munotype’, with variable residual cytotoxicity, that is linked
to a gradient of phenotypes in disease severity (Jessen et al,
2011, 2013b). This concept is illustrated in Fig 1.
Pathogenesis of primary HLH
Animal models of primary HLH have been valuable tools for
unravelling the role of specific proteins in the degranulation
machinery and in HLH pathophysiology. In murine primary
HLH, a major pathogenic role has been attributed to hyper-
activated CTLs and their c-interferon (IFN-c) secretion (Jor-
dan et al, 2004; Pachlopnik Schmid et al, 2009; K€ogl et al,
2013). The activated CTLs infiltrate multiple organs while
producing large amounts of IFN-c that mediates secondary
activation of macrophages, and possibly also fibroblasts and
endothelial cells (Billiau et al, 2005; Put et al, 2015). In turn,
these cells secrete cytokines, such as IL1b, IL6 and tumour
necrosis factor a (TNFa), culminating in a cytokine storm
(Jenkins et al, 2015). Several feedback mechanisms were
identified that normally function to limit this inflammatory
escalation, but are deficient in primary HLH.
Persistent antigenaemia. The first, well-known effector func-
tion of CTLs and NK cells is the clearance of infected cells
and tumour cells. When cytotoxic function is impaired, pro-
liferation of cancerous cells is unrestrained and infectious
triggers fail to be eliminated. The source of antigenic stimu-
lation persists and drives continuous activation and expan-
sion of antigen-specific T cells.
Ongoing antigen presentation. A second effector function of
CTLs ensures essential immunoregulation via a negative feed-
back loop, limiting on-going antigenic stimulation. Through
perforin-dependent killing of a rare subset of antigen-pre-
senting dendritic cells, CTLs suppress prolonged antigen pre-
sentation, thus preventing further T cell activation. In
primary HLH, these dendritic cells persist and increase their
antigen presentation, resulting in uncontrolled CTL activa-
tion (Lykens et al, 2011; Terrell & Jordan, 2013).
Regulatory NK cells. NK cells exert a similar immunoregula-
tory function in primary HLH. Depletion experiments
designated no pathogenic role to NK cells in murine HLH
(Jordan et al, 2004; K€ogl et al, 2013). Instead, models in
which cytotoxic defects were restricted to either NK cells or
CTLs indicated that functioning NK cell cytotoxicity is suffi-
cient to limit hyperactivation and excessive proliferation of
CTLs and to protect from severe HLH pathology (Sepulveda
et al, 2015).
Regulatory T cells. Another immunoregulatory mechanism,
involving regulatory T cells (Tregs), may be defective in pri-
mary HLH. Tregs eliminate activated autologous CTLs in a
perforin- and granzyme-dependent way to curb inflamma-
tion (Verbsky & Grossman, 2006). In normal conditions,
Tregs also indirectly suppress CTL proliferation by preferen-
tially consuming the available IL2. However, Treg homeosta-
sis was reported to be disturbed in murine FHL-2. Reduced
production of IL2 and elevated levels of antagonistic soluble
CD25 limited the availability of IL2. The remaining free IL2
was preferably consumed by hyperactivated CTLs, that
upregulated their CD25 expression to surpass that of Tregs,
inverting the IL2 consumption hierarchy and resulting in a
profound collapse of Treg numbers (Humblet-Baron et al,
2016).
Hypercytokinaemia. Recently, a direct role for defective
granule-mediated cytotoxicity in the development of the
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cytokine storm was unravelled. Cytolytically impaired NK
cells and CTLs failed to disengage from their targets, as the
detachment signal needed to come from the dying target cell,
increasing mean contact times up to fivefold. Prolonged
synapse duration stimulated the effector cells through repeti-
tive Ca2+-signalling to secrete increasing amounts of cytoki-
nes and chemokines, including IFN-c, that directly activated
macrophages, linking cytotoxicity defects to hypercytoki-
naemia and initiation of systemic inflammation (Jenkins
et al, 2015).
IFN-c is considered the major driver of pathology in mur-
ine primary HLH, directly inducing haemophagocytosis and
pancytopenia (Jordan et al, 2004; Pachlopnik Schmid et al,
2009; Zoller et al, 2011). Evidence for a similar role in
humans is less robust. Elevated IFN-c levels are often present
in the sera of primary HLH patients, but not in all patients,
and reported levels vary widely (Henter et al, 1991; Osugi
et al, 1997; Nagasawa et al, 2008; Xu et al, 2012). Further-
more, microarray analysis of peripheral blood mononuclear
cells from primary HLH patients revealed no significant
upregulation of IFN-c expression and a peculiar absence of
IFN-c-induced gene expression. This unexpected finding
might be explained by the upregulation of suppressor-of-
cytokine-signalling-3 (SOCS-3) in patients, which decreases
responsiveness of macrophages to IFN-c, or by downregula-
tion of IFN-c receptor 2. In contrast, pathways related to
IL1, IL6, IL8 and IL10 signalling were significantly upregu-
lated, signifying that, rather than one central player, multiple
cytokines synergize to enhance disease in human HLH
(Sumegi et al, 2011).
Alarmins. Recently a novel cytokine was implicated in the
pathogenesis of murine FHL-2. IL33, a member of the IL1
superfamily, is released from non-haematopoietic cells upon
cellular stress or necrosis, as an alarmin. It can be endocytosed
by lymphocytes to initiate inflammation. IL33 thus stimulates
CTL activation and IFN-c production (Rood et al, 2016). Inter-
estingly, the IL33 receptor, ST2, signals through a myeloid-dif-
ferentiation-primary-response-gene-88 (MyD88)-dependent
pathway. This adaptor protein, required for signalling by IL1
family cytokines and downstream of most toll-like receptors
(TLRs), was already considered a potential therapeutic target in
murine FHL-3 (Krebs et al, 2011). The therapeutic efficacy of
blocking ST2 signalling in murine FHL-2 confirms involvement
of the MyD88 pathway in primary HLH (Rood et al, 2016). The
contribution of danger signals to primary HLH might be under-
estimated. Defective cytotoxicity prevents target cells to be
removed via the immunologically silent process of apoptosis.
Instead, cell death through pyroptosis or necrosis will occur,
resulting in the release of alarmins, instigating additional
inflammation (Palmblad et al, 2014). Thus, two pathogenic
processes possibly synergize to initiate disease in primary HLH:
persistent antigen presentation perpetuates infectious inflamma-
tion, while alarmins effectuate non-infectious inflammation
(Palmblad et al, 2014; Rood et al, 2016).
In conclusion, granule-mediated cytotoxicity is not only
vital for the control of infections and cancers, it exerts
equally essential immunoregulatory functions that limit anti-
gen presentation, restrict CTL activation and regulate cyto-
kine production. Lastly, induction of apoptosis constitutes an
indispensable, immunologically silent process of cell death.
The hypothesis on primary HLH pathogenesis is depicted in
Fig 2.
Secondary HLH
Secondary HLH is clinically identical to primary HLH, but
defined by a lack of family history or (known) genetic defects
Fig 1. Genotype-phenotype correlations in pri-
mary HLH. The type of mutation and affected
gene determine the extent of the cytotoxic
defect in patients. Different genetic combina-
tions (genotype) result in a gradient of remain-
ing cytotoxic function (immunotype) that
correlates with the age of disease onset and dis-
ease severity (phenotype). HLH, haemophago-
cytic lymphohistiocytosis.
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in cytotoxicity, and instigated by events that disrupt immune
homeostasis. Numerous triggering infections and underlying
inflammatory disorders have been reported, resulting in the
further subdivision of infection-associated, malignancy-asso-
ciated and autoinflammation/autoimmunity-associated
forms, described below. Secondary HLH can also arise in
acquired immunodeficiencies, following chemotherapy,
immunosuppression, biological therapy and organ or stem
cell transplantation, events known to imbalance the immune
system (Atteritano et al, 2012; Janka & Lehmberg, 2014;
Ramos-Casals et al, 2014). Rare cases are also described in
inborn metabolic disorders like lysinuric protein intolerance
or biotinidase deficiency. Secondary HLH in metabolic
patients is often atypical, lacking fever or including non-
HLH features like vomiting or acidosis (Janka & Lehmberg,
2014).
Infection-associated secondary HLH
Infection-associated HLH accounts for approximately half of
all adult HLH cases (Ramos-Casals et al, 2014).
Viruses. A wide spectrum of viruses can elicit HLH. Her-
pesviruses lead the ranks, predominantly EBV, both in pri-
mary and secondary HLH. Around 60% of reported
infectious cases coincide with primary infection or reactiva-
tion of latently present herpesviruses (Ramos-Casals et al,
2014). EBV classically infects B cells and nasopharyngeal
epithelial cells, but in HLH it often infects CTLs or, less fre-
quently, NK cells (Kasahara et al, 2001). This peculiar feature
must be kept in mind when considering treatment of EBV-
associated HLH with B-cell targeting rituximab. EBV viral
load is considered a prognostic factor and correlates with
disease severity in patients. Up to 104 times higher viral titres
are detected in EBV-associated HLH, compared to infectious
mononucleosis. A predisposition to EBV-HLH appears to be
present in Asia. Some have theorized a more virulent strain
could underlie the higher incidence, others report no
predominance of particular substrains (Kasahara et al, 2001;
Teramura et al, 2002; Rouphael et al, 2007; George, 2014).
Aside from EBV, predominantly cytomegalovirus, but also
herpes simplex virus (HSV), human herpesvirus-6 and -8,
varicella zoster, parvovirus B19 and adenoviruses are known
to trigger HLH. Less frequently, HLH is elicited by RNA
viruses, including influenza and enteroviruses. Patients suf-
fering human immunodeficiency virus (HIV) infection are
prone to develop HLH upon opportunistic infections (Rou-
phael et al, 2007; George, 2014; Ramos-Casals et al, 2014).
Recently, the resemblance of viral haemorrhagic fever,
induced by Ebola virus, hantavirus or dengue virus, to HLH
has been described (Cron et al, 2015).
Bacteria, parasites and fungi. Bacteria induce approximately
9% of reported adult HLH cases. Most commonly, HLH is
associated with Mycobacterium infection, even vaccination
with the attenuated Bacillus Calmette-Guerin may trigger
HLH. Less frequently, HLH can arise during infections with
Rickettsia, Staphylococcus, Ehrlichia, Mycoplasma and others.
Parasitic infections account for nearly 25% of adult HLH
cases. The most potent protozoan trigger is Leishmania; in
particular, visceral leishmaniasis progresses to HLH. Plasmod-
ium and Toxoplasma can also elicit HLH.
More sporadically, fungi can induce HLH episodes, mostly
in immunocompromised individuals, including patients with
HIV, primary immunodeficiency or post-transplantation.
Cases associated with Histoplasma, Candida and Cryptococcus
have been described, amongst others (Rouphael et al, 2007;
George, 2014; Ramos-Casals et al, 2014).
Malignancy-associated secondary HLH
HLH complicating malignancies is predominantly regarded a
challenge of adult haematology/oncology, accounting for 15–
50% of adult HLH cases. The likelihood of developing malig-
nancy-associated HLH increases with age. Nonetheless, cases
may be observed in children and adolescents. The most
Fig 2. Hypothesized pathogenesis of primary HLH. (A) Normal situation: 1. CTLs and NK cells eliminate tumour cells and/or infected cells via
apoptosis. 2. When the immunological stimulus is cleared, the CTLs will inhibit further antigen presentation by removing antigen-presenting
DCs. 3. Tregs compete with the activated CTLs for the available IL2 and thus limit the proliferation of CTLs. They may also directly eliminate
activated CTLs. 4. NK cells likewise control the size of the activated CTL pool via induction of apoptosis. 5. This limits the amount of CTL-
derived IFN-c and consequently the extent of macrophage activation and additional cytokine production. (B) In the setting of primary HLH: 1.
CTLs and NK cells fail to eliminate tumour cells and/or infected cells, which continue to replicate, resulting in persistent antigenaemia. 2. CTLs
no longer remove the antigen-presenting DCs, leading to prolonged and heightened antigen presentation, stimulating antigen-specific T cells.
1+2. The inability of CTLs and NK cells to eliminate target cells causes an increase in synapse time, stimulating the effector cells to produce more
cytokines. 3. Tregs can no longer outcompete the hyperactivated CTLs for the lower amount of available IL2 because the expression of CD25 is
more highly upregulated in the latter. Treg numbers drop and CTLs continue to proliferate. 4. Similarly, lacking their cytotoxic capacity, NK cells
no longer control the size of the activated CTL pool. 5. The activated CTLs produce massive amounts of IFN-c inducing excessive macrophage
activation and directly provoking haemophagocytosis. In turn, the activated macrophages produce enormous amounts of pro-inflammatory
cytokines, creating a cytokine storm. 6. As cells can no longer be eliminated via immunologically silent apoptosis, necrosis and/or pyroptosis will
occur, resulting in the release of DAMPs that instigate further inflammation. Solid black arrows indicate the effective function of the processes as
described by the numbers written above them (A), dotted black arrows indicate impaired function of these processes (B). Red arrows refer to the
competition for available IL2 consumption (A+B). HLH, haemophagocytic lymphohistiocytosis; CTL, cytotoxic T lymphocyte; DAMP, danger-
associated molecular pattern; DC, dendritic cell; Mφ, macrophage; MHC, major histocompatibility complex; NK, natural killer; RBC, red blood
cell; Treg, regulatory T cell.
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common underlying cancers are lymphomas, mostly T/NK
cell, but also B cell lymphomas, and leukaemia. Association
with solid tumours is rare. The neoplasm itself might trigger
HLH, with aberrant cytokine production by malignant cells
constituting a pathophysiological mechanism. Conversely,
HLH may occur during chemotherapy, induced by infec-
tions, linking disease onset to therapy-induced immunosup-
pression. Often, EBV is involved, either as a co-trigger or
causing the underlying malignancy. Interestingly, HLH-
related mutations can predispose to both haematological
malignancies and HLH (George, 2014; Ramos-Casals et al,
2014; Lehmberg et al, 2015a,b; L€ofstedt et al, 2015).
Secondary HLH associated with autoimmune or
autoinflammatory diseases
Secondary HLH complicating autoimmune and autoinflam-
matory disorders is most frequently reported in systemic
juvenile idiopathic arthritis (sJIA). 10% of sJIA patients
develops clinically overt HLH, while 50% shows subclinical
evidence of HLH. Secondary HLH also occurs in systemic
lupus erythematosus, adult-onset Still’s disease, Kawasaki dis-
ease and, sporadically, in rheumatoid arthritis, dermato-
myositis, sarcoidosis, systemic sclerosis, polyarteritis nodosa
and inflammatory bowel disease. HLH complicating rheuma-
tological conditions is often referred to as ‘macrophage acti-
vation syndrome’ (MAS) (Atteritano et al, 2012; Ramos-
Casals et al, 2014; Zhang et al, 2014b).
Pathogenesis of secondary HLH
Acquired defects in cytotoxicity. Compared to primary HLH,
the pathophysiological mechanisms driving secondary HLH
remain incompletely understood. Patients can exhibit reduced
NK cell and/or CTL cytotoxicity, similar to primary HLH.
This has been attributed to decreased perforin expression in
some cases and reduced numbers of peripheral blood NK cells
in others. However, in secondary HLH, the NK cell dysfunc-
tion is not intrinsic but acquired. It is a transient defect that
typically normalizes with disease remission or reverses upon
IL2 stimulation in vitro (Grom et al, 2003; Ramanan & Sch-
neider, 2003; Grom, 2004; Bryceson et al, 2012).
The cytokine storm is hypothesized to impair NK cell
cytotoxicity in secondary HLH. Persistent high levels of
otherwise NK cell-stimulating cytokines, like IL12 or IL18,
might overactivate NK cells, predisposing to activation-
induced apoptosis, or cause exhaustion and insensitivity to
further cytokine stimulation (Avau et al, 2015; Canna &
Goldbach-Mansky, 2015). Recent evidence indicates chronic
IL6 exposure is involved. Perforin and granzyme B expres-
sion of NK cells was reduced in IL6-overexpressing mice,
resulting in defective cytotoxicity. Treatment of human NK
cells with tocilizumab, an anti-IL6 antibody, increased per-
forin and granzyme B expression, enhancing their cytotoxic
capacity (Cifaldi et al, 2015).
In addition to continuous cytokine exposure, several infec-
tious agents are capable of suppressing CTL and/or NK cell
cytotoxicity. The latent-membrane-protein-1 of EBV is capable
of inhibiting SAP expression in T cells, creating a setting remi-
niscent of XLP1-associated HLH (Chuang et al, 2005). The
haemagglutinin protein of H5N1 influenza reduces perforin
expression in CTLs, impairing their cytotoxicity and allowing
the persistence of stimulatory H5 antigen-presenting dendritic
cells (Hsieh & Chang, 2006). H1N1 influenza is described to
infect and replicate in human NK cells and to induce apoptosis,
contributing to decreased NK cell numbers and cytotoxic func-
tion (Mao et al, 2009). Many viruses encode anti-apoptotic
proteins that delay apoptosis of infected cells, which was
recently linked to prolonged cytotoxic synapse duration and
cytokine hypersecretion, contributing to HLH pathogenesis
(Jenkins et al, 2015). Amongst others, EBV and HSV-1 can ren-
der cells resistant to CTL-induced apoptosis (Jerome et al,
1998). Similarly, tumour cells are often resistant to apoptosis,
thus prolonged synapse formation could also contribute to
malignancy-associated HLH (Jenkins et al, 2015).
Innate immune activation. Although acquired defects in CTL
and/or NK cell cytotoxicity have been described in secondary
HLH, the majority (approximately 75%) of patients presents
with normal cytotoxicity (Bryceson et al, 2012), indicating
that alternative mechanisms can drive disease. Animal models
of secondary HLH highlight the involvement of innate
immune activation, through chronic or excessive stimulation
of pattern recognition receptors like TLRs. Repeated stimula-
tion of TLR9 resulted in several hallmark features of HLH in a
mouse model of MAS. Depletion studies revealed no signifi-
cant role for CTLs in this model, as opposed to their major
role in primary HLH. Instead, disease was driven by overacti-
vation of innate immune pathways (Behrens et al, 2011). Sin-
gle, excessive stimulation of TLR9 was also reported to induce
murine HLH, emphasizing the role of TLR activation in sec-
ondary HLH (Ohyagi et al, 2013). Notably, EBV also activates
TLR9 signalling (Behrens et al, 2011).
Exaggerated signalling of TLRs has been connected to HLH
pathogenesis in another model, in which IL6-transgenic mice
display aberrant responses to TLR ligands. Constitutively high
IL6 expression excessively amplified the inflammatory
response to Poly(I:C), CpG, lipoteichoic acid and lipopolysac-
charide, the latter inducing fulminant HLH. Thus, prolonged
exposure to IL6, as observed in different autoimmune and
autoinflammatory diseases, not only impairs NK cell cytotoxi-
city but also derails the immune system towards hyperinflam-
matory responses (Strippoli et al, 2012; Cifaldi et al, 2015).
Excessive inflammasome activation might also fuel inflam-
mation in secondary HLH, as recently described in MAS
patients carrying NLRC4 gain-of-function mutations. Such
mutations result in caspase-1 overactivation, excessive IL18
production and systemic macrophage activation, underscor-
ing the involvement of innate pathways in secondary HLH
(Canna & Goldbach-Mansky, 2015).
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Role of IFN-c. The role of IFN-c, the central cytokine in pri-
mary HLH, has been challenged in secondary HLH by several
findings. In the IL6-transgenic mouse model, neutralization of
IFN-c effectively improved survival and clinical parameters
(Prencipe et al, 2015), while in a novel virus-associated sec-
ondary HLH model, IFN-c-deficient mice displayed an exacer-
bated phenotype (Brisse et al, 2016). In the TLR9-triggered
mouse model, the impact of IFN-c was conditional to the dis-
ease-modulating effect of IL10. During IL10-receptor block-
ade, when most severe MAS was observed, only the
development of anaemia was IFN-c-restricted. Characteristic
HLH symptoms like haemophagocytosis, hyperferritinaemia,
hepatitis, splenomegaly and thrombocytopenia still developed
in the absence of IFN-c (Behrens et al, 2011; Canna et al,
2013; Brisse et al, 2016). Thus, cytokines other than IFN-c can
drive disease in secondary HLH. Probably multiple mecha-
nisms, adaptive or innate, can underlie HLH pathogenesis.
A blurring distinction between primary and
secondary HLH
Traditionally, primary HLH was defined by the presence of
homozygous mutations in cytotoxicity-related genes. Con-
versely, secondary HLH was classically determined to have
no genetic background. Evidence is currently accumulating
for genetic overlap between both. In some patients with
classical ‘secondary’ HLH, monoallelic mutations or poly-
morphisms have been detected in genes typically implicated
in primary HLH (Table II) (Kaufman et al, 2014; Wang
et al, 2014; Zhang et al, 2014a,b). Some of these polymor-
phisms are relatively frequent in the general population (up
to 9% minor allele frequency for PRF1 A91V), while several
base changes, present in non-conserved gene regions, are
predicted in silico to be benign. Therefore it remains uncer-
tain how they relate to HLH pathogenesis. Presumably they
are not clinically neutral given their enrichment in patients
with secondary HLH compared to healthy or inflammatory
controls (Zhang et al, 2008a; Vastert et al, 2010; Kaufman
et al, 2014). Only one study reported no enrichment of
monoallelic rare variants in secondary HLH, compared to a
large healthy control cohort (Tesi et al, 2015b). Theoreti-
cally, hypomorphic single-copy mutations may alter protein
levels and thus induce subtle impairment of cytotoxicity,
increasing susceptibility to infections. Interestingly, heterozy-
gous mutations in PRF1 and LYST have also been impli-
cated in severe H1N1 influenza (Schulert et al, 2016),
suggesting the sequence variants are not strictly recessive
but may generate haploinsufficiency for cytotoxicity genes
(Zhang et al, 2011, 2014a,b; Tesi et al, 2015b; Cetica et al,
2016).
The discovery of heterozygous defects in secondary HLH
has reduced its distinction with late-onset/atypical primary
HLH to a matter of semantics. Both subtypes comprise
heterozygous monogenic, bigenic or polygenic subgroups
(Kaufman et al, 2014; de Saint Basile et al, 2015).
Nonetheless, patients carrying typical primary HLH-linked
mutations or polymorphisms account for only a minor per-
centage of secondary HLH, approximately 7–18% in the lar-
gest cohorts (Zhang et al, 2011, 2014a; Wang et al, 2014;
Cetica et al, 2016), signifying the existence of other predis-
posing factors in the majority of secondary HLH patients.
Extensive whole-exome sequencing in secondary HLH
patients has revealed homozygous, compound heterozygous
and heterozygous protein-altering mutations in non-primary
HLH-related genes as well. Some of these genes were indi-
rectly involved in the cytolytic pathway, e.g. encoding regula-
tors of actin and microtubule reorganization or vesicle-
mediated transport (Table II). As mutations in these genes
were enriched in secondary HLH patients, they also deserve
attention as new gene candidates in primary HLH (Kaufman
et al, 2014).
Mutations and polymorphisms in non-cytotoxicity-related
genes, affecting NK cell receptors, cytokine production, cyto-
kine signalling, inflammasome activation and TLR signalling,
may also predispose to secondary HLH (Table II). Polymor-
phisms in activating killer cell immunoglobulin-like receptors
or in IL10 and TGFB constitute risk factors for EBV-asso-
ciated HLH (Hatta et al, 2007; Qiang et al, 2012; Wang et al,
2015). Noteworthy, IL10 fulfils a protective function in HLH
animal models (reviewed in Brisse et al, 2015) and IL10
polymorphisms associated with low IL10 production are
enriched in sJIA patients, which might relate to their suscep-
tibility to HLH (Fife et al, 2006). Recently, the first report
appeared of two IFN-c-receptor-deficient patients who
Table II. Genetic factors in secondary haemophagocytic lymphohisti-
ocytosis
Polymorphisms contributing to secondary haemophagocytic
lymphohistiocytosis susceptibility
Granule-mediated cytotoxicity
PRF1, UNC13D, STX11, STXBP2, RAB27A, SH2D1A, LYST
Microtubule organization
CCDC141, XIRP2, ARHGAP21, MICAL2
Vesicle transport
FAM160A2, EXPH5, CADPS2, FKBPL, GDI1
NK cell receptors
KIR2DS5, KIR3DS1
Cytokine production and signalling
IL10, TGFB, IFNGR1, IFNGR2, NLRC4, IRF5
Inflammasome activation
NLRC4
TLR signalling
IRF5
Primary immunodeficiency genes
IL2RG, RAG1, CD127, CD3E, GATA2, CD27, ITK, MAGT1, BTK,
FAS, NLRP3, MEFV, TNFRSF1A, IKBKG, STAT1, WAS, ATM,
CYBB, 22q11.2 deletion
Function unknown
LRGUK
NK, natural killer; TLR, Toll-like receptor.
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Fig 3. Threshold model of the HLH spectrum. Genetic factors (as explained in Fig 1), background inflammation (as contributed by underlying
immune disorders and/or malignancies), underlying immunosuppression and different strengths of infectious triggers are superimposed until a
certain threshold point is reached, beyond which inflammation is no longer controlled and fulminant HLH develops. Diverse pathways and aeti-
ologies can thus result in the same common end stage of HLH. EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; HLH, hae-
mophagocytic lymphohistiocytosis; IBD, inflammatory bowel disease; MAS, macrophage activation syndrome; RA, rheumatoid arthritis; sJIA,
systemic juvenile idiopathic arthritis; SLE, systemic lupus erythematosus.
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acquired HLH in the absence of functional IFN-c-signalling,
constituting formal proof that HLH can emerge independent
of IFN-c, not only in animal models (Canna et al, 2013), but
also in humans (Tesi et al, 2015c). Secondary HLH patients
carrying heterozygous NLRC4 mutations have also been
described (Canna & Goldbach-Mansky, 2015). Lastly, activat-
ing polymorphisms in IRF5, a TLR-signalling molecule and
master transcription factor for pro-inflammatory cytokines,
were associated with susceptibility to secondary HLH
(Yanagimachi et al, 2011a,b).
Furthermore, HLH can complicate various monogenic
disorders. Categorizing these cases as primary or secondary
HLH is challenging, as the extent to which the underlying
mutations contribute to HLH is unknown (Table II). HLH
occurs most frequently in primary immunodeficient (PID)
patients with severe T or NK cell deficiencies, for instance
due to IL2RG or RAG-1 mutations. In these patients, who
are profoundly lymphopenic, HLH seems to develop
independently of T or NK cells and is generally linked to
impaired viral control (Faitelson & Grunebaum, 2014; Bode
et al, 2015). Patients carrying CD27, ITK or MAGT1 muta-
tions show increased susceptibility to EBV-induced HLH.
Arguably, these cases could be classified as primary HLH,
analogous to XLP (Lehmberg et al, 2015a). HLH in myeloid
PIDs, such as chronic granulomatous disease, is less
frequent and mostly associated with bacterial infections
(Faitelson & Grunebaum, 2014; Bode et al, 2015). Rarely,
other monogenic autoinflammatory disorders are compli-
cated by HLH, including familial Mediterranean fever and
cryoperin-associated periodic syndrome (Rigante et al,
2015), which involve spontaneous inflammasome activation,
similar to NLRC4-associated HLH (Canna & Goldbach-
Mansky, 2015).
Thus, although formerly only primary HLH was thought
to involve genetic factors, some degree of genetic predisposi-
tion may also be implicated in secondary HLH.
Conclusion: HLH as a threshold disease
Based on the presented arguments, HLH can no longer be
considered a binary disorder, divided into ‘genetic’ or ‘ac-
quired’ forms. HLH rather represents a continuum in which
diverse aetiologies and pathogenic mechanisms result in the
same endpoint of a fulminant haemophagocytic syndrome.
In this regard, HLH can be portrayed as a ‘threshold’ disease
(Fig 3). The weight of different predisposing factors is com-
bined until a threshold is exceeded, above which inflamma-
tion is no longer controlled. Endogenous components, such
as genetic factors, determine the residual cytotoxic function
of patients, while underlying disorders contribute to back-
ground inflammation. Concomitant immunosuppression
may cause further imbalance in immune homeostasis and
influence host susceptibility to exogenous triggers, including
infections of variable severity. By combined action of these
diverse factors, a wide spectrum of HLH can develop, rang-
ing from typical FHL to infection-associated secondary HLH
(Strippoli et al, 2013; de Saint Basile et al, 2015; Cetica et al,
2016).
Acknowledgements
This work was supported by the Agency for Innovation by
Science and Technology (IWT), Flanders’ Regional Govern-
ment (GOA programme) and the Interuniversity Attraction
Poles (IAP). E.B. received an IWT fellowship. We thank Pro-
fessor Billiau for critically reviewing the manuscript. The
authors declare no conflicting interests.
Author contributions
E.B. has written the review article. C.H.W. and P.M. have
thoroughly and critically revised the manuscript.
References
Atteritano, M., David, A., Bagnato, G., Beninati, C.,
Frisina, A., Iaria, C. & Cascio, A. (2012) Hae-
mophagocytic syndrome in rheumatic patients.
A systematic review. European Review for Medical
and Pharmacological Sciences, 16, 1414–24.
Avau, A., Put, K., Wouters, C.H. & Matthys, P.
(2015) Cytokine balance and cytokine-driven
natural killer cell dysfunction in systemic juve-
nile idiopathic arthritis. Cytokine & Growth Fac-
tor Reviews, 26, 35–45.
Behrens, E.M., Canna, S.W., Slade, K., Rao, S.,
Kreiger, P.A., Paessler, M., Kambayashi, T. &
Koretzky, G.A. (2011) Repeated TLR9 stimula-
tion results in macrophage activation syndrome
– like disease in mice. The Journal of Clinical
Investigation, 121, 2264–2277.
Billiau, A.D., Roskams, T., Van Damme-Lom-
baerts, R., Matthys, P. & Wouters, C. (2005)
Macrophage activation syndrome: characteristic
findings on liver biopsy illustrating the key role
of activated, IFN-gamma-producing lympho-
cytes and IL-6- and TNF-alpha-producing
macrophages. Blood, 105, 1648–51.
Bode, S.F.N., Ammann, S., Al-Herz, W., Bataneant,
M., Dvorak, C.C., Gehring, S., Gennery, A., Gil-
mour, K.C., Gonzalez-Granado, L.I., GroB-
Wieltsch, U., Ifversen, M., Lingman-Framme, J.,
Matthes-Martin, S., Mesters, R., Meyts, I., van
Montfrans, J.M., Pachlopnik Schmid, J., Pai, S.-
Y., Soler-Palacin, P., Schuermann, U., Schuster,
V., Seidel, M.G., Speckmann, C., Stepensky, P.,
Sykora, K.-W., Tesi, B., Vraetz, T., Waruiru, C.,
Bryceson, Y.T., Moshous, D., Lehmberg, K., Jor-
dan, M.B. & Ehl, S. (2015) The syndrome of
hemophagocytic lymphohistiocytosis in primary
immunodeficiencies: implications for differential
diagnosis and pathogenesis. Haematologica, 100,
978–988.
Brisse, E., Wouters, C.H. & Matthys, P. (2015)
Hemophagocytic lymphohistiocytosis (HLH): a
heterogeneous spectrum of cytokine-driven
immune disorders. Cytokine & Growth Factor
Reviews, 26, 263–280.
Brisse, E., Imbrechts, M., Put, K., Avau, A., Mitera,
T., Berghmans, N., Rutgeerts, O., Waer, M.,
Ninivaggi, M., Kelchtermans, H., Boon, L.,
Snoeck, R., Andrei, G. & Matthys, P. (2016)
Mouse cytomegalovirus infection in BALB/c
mice resembles virus-associated secondary
hemophagocytic lymphohistiocytosis and shows
a pathogenesis distinct from primary
hemophagocytic lymphohistiocytosis. The Jour-
nal of Immunology, 196, 3124–3134.
Bryceson, Y.T., Pende, D., Maul-Pavicic, A., Gil-
mour, K.C., Ufheil, H., Vraetz, T., Chiang, S.C.,
Marcenaro, S., Meazza, R., Bondzio, I., Walshe,
D., Janka, G., Lehmberg, K., Beutel, K., zur
Stadt, U., Binder, N., Arico, M., Moretta, L.,
Review
ª 2016 John Wiley & Sons Ltd, British Journal of Haematology 11
Henter, J.I. & Ehl, S. (2012) A prospective eval-
uation of degranulation assays in the rapid diag-
nosis of familial hemophagocytic syndromes.
Blood, 119, 2754–2763.
Canna, S.W. & Goldbach-Mansky, R. (2015) New
monogenetic autoinflammatory diseases—a clin-
ical overview. Seminars in Immunopathology, 37,
387–394.
Canna, S.W., Wrobel, J., Chu, N., Kreiger, P.A.,
Paessler, M. & Behrens, E.M. (2013) Inter-
feron-c mediates anemia but is dispensable for
fulminant toll-like receptor 9-induced macro-
phage activation syndrome and hemophagocy-
tosis in mice. Arthritis and Rheumatism, 65,
1764–75.
Cetica, V., Sieni, E., Pende, D., Danesino, C., De
Fusco, C., Locatelli, F., Micalizzi, C., Putti,
M.C., Biondi, A., Fagioli, F., Moretta, L., Grif-
fiths, G.M., Luzzatto, L. & Arico, M. (2016)
Genetic predisposition to hemophagocytic lym-
phohistiocytosis: report on 500 patients from
the Italian registry. The Journal of Allergy and
Clinical Immunology, 137, 188–196.
Chuang, H.-C., Lay, J.-D., Hsieh, W.-C., Wang,
H.-C., Chang, Y., Chuang, S.-E. & Su, I.-J.
(2005) Epstein-Barr virus LMP1 inhibits the
expression of SAP gene and upregulates Th1
cytokines in the pathogenesis of hemophagocytic
syndrome. Blood, 106, 3090–6.
Cifaldi, L., Prencipe, G., Caiello, I., Bracaglia,
C., Locatelli, F., De Benedetti, F. & Strippoli,
R. (2015) Inhibition of natural killer cell
cytotoxicity by interleukin-6: implications for
the pathogenesis of macrophage activation
syndrome. Arthritis & Rheumatology, 67,
3037–46.
Cron, R.Q., Behrens, E.M., Shakoory, B., Rama-
nan, A.V. & Chatham, W.W. (2015) Does viral
hemorrhagic fever represent reactive
hemophagocytic syndrome? The Journal of
Rheumatology, 42, 1078–1080.
D’Orlando, O., Zhao, F., Kasper, B., Orinska, Z.,
M€uller, J., Hermans-Borgmeyer, I., Griffiths,
G.M., Zur Stadt, U. & Bulfone-Paus, S. (2013)
Syntaxin 11 is required for NK and CD8+ T-cell
cytotoxicity and neutrophil degranulation. Euro-
pean Journal of Immunology, 43, 194–208.
Dotta, L., Parolini, S., Prandini, A., Tabellini, G.,
Antolini, M., Kingsmore, S.F. & Badolato, R.
(2013) Clinical, laboratory and molecular signs
of immunodeficiency in patients with partial
oculo-cutaneous albinism. Orphanet Journal of
Rare Diseases, 8, 168–177.
Enders, A., Zieger, B., Schwarz, K., Yoshimi, A.,
Speckmann, C., Knoepfle, E.-M., Kontny, U.,
M€uller, C., Nurden, A., Rohr, J., Henschen, M.,
Pannicke, U., Niemeyer, C., Nurden, P. & Ehl,
S. (2006) Lethal hemophagocytic lymphohistio-
cytosis in Hermansky-Pudlak syndrome type II.
Blood, 108, 81–7.
Entesarian, M., Chiang, S.C.C., Schlums, H.,
Meeths, M., Chan, M.-Y., Mya, S.-N., Soh, S.-Y.,
Nordenskj€old, M., Henter, J.-I. & Bryceson, Y.T.
(2013) Novel deep intronic and missense
UNC13D mutations in familial
haemophagocytic lymphohistiocytosis type 3.
British Journal of Haematology, 162, 415–8.
Faitelson, Y. & Grunebaum, E. (2014)
Hemophagocytic lymphohistiocytosis and pri-
mary immune deficiency disorders. Clinical
Immunology, 155, 118–125.
Fife, M.S., Gutierrez, A., Ogilvie, E.M., Stock,
C.J.W., Samuel, J.M., Thomson, W., Mack, L.F.,
Lewis, C.M. & Woo, P. (2006) Novel IL10 gene
family associations with systemic juvenile idio-
pathic arthritis. Arthritis Research & Therapy, 8,
R148.
Gao, L., Dang, X., Huang, L., Zhu, L., Fang, M.,
Zhang, J., Xu, X., Zhu, L., Li, T., Zhao, L., Wei,
J. & Zhou, J. (2016) Search for the potential
‘second-hit’ mechanism underlying the onset of
familial hemophagocytic lymphohistiocytosis
type 2 by whole-exome sequencing analysis.
Translational Research, 170, 26–39.
George, M.R. (2014) Hemophagocytic lymphohis-
tiocytosis: review of etiologies and management.
Journal of Blood Medicine, 5, 69–86.
Grom, A.A. (2004) Natural killer cell dysfunction:
a common pathway in systemic-onset juvenile
rheumatoid arthritis, macrophage activation
syndrome, and hemophagocytic lymphohistiocy-
tosis? Arthritis and Rheumatism, 50, 689–98.
Grom, A., Villanueva, J., Lee, S., Goldmuntz, E.,
Passo, M. & Filipovich, A.H. (2003) Natural
killer cell dysfunction in patients with systemic-
onset rheumatoid arthritis and macrophage acti-
vation syndrome. Journal of Pediatrics, 29, 2–
296.
Hackmann, Y., Graham, S.C., Ehl, S., Honing, S.,
Lehmberg, K., Arico, M., Owen, D.J. & Grif-
fiths, G.M. (2013) Syntaxin binding mechanism
and disease-causing mutations in Munc18-2.
Proceedings of the National Academy of Sciences
of the United States of America, 110, E4482–
E4491.
Hatta, K., Morimoto, A., Ishii, E., Kimura, H.,
Ueda, I., Hibi, S., Todo, S., Sugimoto, T. &
Imashuku, S. (2007) Association of transforming
growth factor-beta1 gene polymorphism in the
development of Epstein-Barr virus-related hema-
tologic diseases. Haematologica, 92, 1470–4.
Henter, J.I., Elinder, G., S€oder, O., Hansson, M.,
Andersson, B. & Andersson, U. (1991) Hypercy-
tokinemia in familial hemophagocytic lympho-
histiocytosis. Blood, 78, 2918–2922.
Holle, J.R., Marsh, R.A., Holdcroft, A.M., Davies,
S.M., Wang, L., Zhang, K. & Jordan, M.B.
(2015) Hemophagocytic lymphohistiocytosis in
a female patient due to a heterozygous XIAP
mutation and skewed X chromosome inactiva-
tion. Pediatric Blood & Cancer, 62, 1288–1290.
Horne, A., Ramme, K.G., Rudd, E., Zheng, C.,
Wali, Y., Al-Lamki, Z., G€urgey, A., Yalman, N.,
Nordenskj€old, M. & Henter, J.I. (2008) Charac-
terization of PRF1, STX11 and UNC13D geno-
type-phenotype correlations in familial
hemophagocytic lymphohistiocytosis. British
Journal of Haematology, 143, 75–83.
Hsieh, S. & Chang, S. (2006) Cutting edge: insuffi-
cient perforin expression in CD8+ T cells in
response to hemagglutinin from avian influenza
(H5N1) virus. The Journal of Immunology, 176,
4530–4533.
Humblet-Baron, S., Franckaert, D., Dooley, J.,
Bornschein, S., Cauwe, B., Sch€onefeldt, S., Bos-
suyt, X., Matthys, P., Baron, F., Wouters, C. &
Liston, A. (2016) IL-2 consumption by highly
activated CD8 T cells induces regulatory T-cell
dysfunction in patients with hemophagocytic
lymphohistiocytosis. The Journal of Allergy and
Clinical Immunology. doi:10.1016/j.jaci.2015.
12.1314
Janka, G.E. & Lehmberg, K. (2014) Hemophago-
cytic syndromes - An update. Blood Reviews, 28,
135–142.
Jenkins, M.R., Rudd-Schmidt, J.A., Lopez, J.A.,
Ramsbottom, K.M., Mannering, S.I., Andrews,
D.M., Voskoboinik, I. & Trapani, J.A. (2015)
Failed CTL/NK cell killing and cytokine hyper-
secretion are directly linked through prolonged
synapse time. Journal of Experimental Medicine,
212, 307–317.
Jerome, K.R., Tait, J.F., Koelle, D.M. & Corey, L.
(1998) Herpes simplex virus type 1 renders
infected cells resistant to cytotoxic T-lympho-
cyte-induced apoptosis. Journal of Virology, 72,
436–41.
Jessen, B., Maul-Pavicic, A., Ufheil, H., Vraetz, T.,
Enders, A., Lehmberg, K., L€angler, A., Gross-
Wieltsch, U., Bay, A., Kaya, Z., Bryceson, Y.T.,
Koscielniak, E., Badawy, S., Davies, G., Huf-
nagel, M., Schmitt-Graeff, A., Aichele, P., Zur
Stadt, U., Schwarz, K. & Ehl, S. (2011) Subtle
differences in CTL cytotoxicity determine sus-
ceptibility to hemophagocytic lymphohistiocyto-
sis in mice and humans with Chediak-Higashi
syndrome. Blood, 118, 4620–9.
Jessen, B., Bode, S.F., Ammann, S., Chakravorty,
S., Davies, G., Diestelhorst, J., Frei-Jones, M.,
Gahl, W.A., Gochuico, B.R., Griese, M., Grif-
fiths, G., Janka, G., Klein, C., Kogl, T., Kur-
nik, K., Lehmberg, K., Maul-Pavicic, A.,
Mumford, A.D., Pace, D., Parvaneh, N.,
Rezaei, N., de Saint Basile, G., Schmitt-Graeff,
A., Schwarz, K., Karasu, G.T., Zieger, B., Zur
Stadt, U., Aichele, P. & Ehl, S. (2013a) The
risk of hemophagocytic lymphohistiocytosis in
Hermansky-Pudlak syndrome type 2. Blood,
121, 2943–2951.
Jessen, B., K€ogl, T., Sepulveda, F.E., de Saint
Basile, G., Aichele, P. & Ehl, S. (2013b) Graded
defects in cytotoxicity determine severity of
hemophagocytic lymphohistiocytosis in humans
and mice. Frontiers in Immunology, 4, e448.
Jordan, M.B., Hildeman, D., Kappler, J. & Mar-
rack, P. (2004) An animal model of
hemophagocytic lymphohistiocytosis (HLH):
CD8+ T cells and interferon gamma are essential
for the disorder. Blood, 104, 735–743.
Kasahara, Y., Yachie, A., Takei, K., Kanegane, C.,
Okada, K., Ohta, K., Seki, H., Igarashi, N., Mar-
uhashi, K., Katayama, K., Katoh, E., Terao, G.,
Sakiyama, Y. & Koizumi, S. (2001) Differential
cellular targets of Epstein-Barr virus (EBV)
infection between acute EBV-associated
Review
12 ª 2016 John Wiley & Sons Ltd, British Journal of Haematology
hemophagocytic lymphohistiocytosis and
chronic active EBV infection. Blood, 98, 1882–
1888.
Kaufman, K.M., Linghu, B., Szustakowski, J.D.,
Husami, A., Yang, F., Zhang, K., Filipovich, A.,
Fall, N., Harley, J.B., Nirmala, N.R. & Grom,
A.A. (2014) Whole exome sequencing reveals
overlap between macrophage activation syn-
drome in systemic juvenile idiopathic arthritis
and familial hemophagocytic lymphohistiocyto-
sis. Arthritis & Rheumatism, 66, 3486–3495.
K€ogl, T., M€uller, J., Jessen, B., Schmitt-graeff, A.,
Janka, G., Ehl, S., zur Stadt, U., Aichele, P. &
Ko, T. (2013) Hemophagocytic lymphohistiocy-
tosis in syntaxin-11-deficient mice: T-cell
exhaustion limits fatal disease. Blood, 121, 604–
613.
Kostova, E.B., Beuger, B.M., Veldthuis, M., van
der Werff ten Bosch, J., K€uhnle, I., van den
Akker, E., van den Berg, T.K., van Zwieten, R.
& van Bruggen, R. (2015) Intrinsic defects in
erythroid cells from familial hemophagocytic
lymphohistiocytosis type 5 patients identify a
role for STXBP2/Munc18-2 in erythropoiesis
and phospholipid scrambling. Experimental
Hematology, 43, 1072–1076.
Krebs, P., Crozat, K., Popkin, D., Oldstone, M.B.
& Beutler, B. (2011) Disruption of MyD88 sig-
naling suppresses hemophagocytic lymphohistio-
cytosis in mice. Blood, 117, 6582–8.
Lehmberg, K., Nichols, K.E., Henter, J.-I.,
Girschikofsky, M., Greenwood, T., Jordan, M.,
Kumar, A., Minkov, M., La Rosee, P. & Weitz-
man, S.; Study Group on Hemophagocytic
Lymphohistiocytosis Subtypes of the Histiocyte
Society (2015a) Consensus recommendations
for the diagnosis and management of
hemophagocytic lymphohistiocytosis associated
with malignancies. Haematologica, 100, 997–
1004.
Lehmberg, K., Sprekels, B., Nichols, K.E., Woess-
mann, W., M€uller, I., Suttorp, M., Bernig, T.,
Beutel, K., Bode, S.F.N., Kentouche, K., Kolb,
R., L€angler, A., Minkov, M., Schilling, F.H., Sch-
mid, I., Vieth, S., Ehl, S., Zur Stadt, U. & Janka,
G.E. (2015b) Malignancy-associated
haemophagocytic lymphohistiocytosis in chil-
dren and adolescents. British Journal of Haema-
tology, 170, 539–549.
L€ofstedt, A., Chiang, S.C.C., Onel€ov, E., Bryceson,
Y.T., Meeths, M. & Henter, J.-I. (2015) Cancer
risk in relatives of patients with a primary disor-
der of lymphocyte cytotoxicity: a retrospective
cohort study. The Lancet. Haematology, 2, e536–
42.
Lykens, J.E., Terrell, C.E., Zoller, E.E., Risma, K. &
Jordan, M.B. (2011) Perforin is a critical physio-
logic regulator of T-cell activation. Blood, 118,
618–26.
Mao, H., Tu, W., Qin, G., Law, H.K.W., Sia, S.F.,
Chan, P.-L., Liu, Y., Lam, K.-T., Zheng, J.,
Peiris, M. & Lau, Y.-L. (2009) Influenza virus
directly infects human natural killer cells and
induces cell apoptosis. Journal of Virology, 83,
9215–22.
Marsh, R.a., Madden, L., Kitchen, B.J., Mody, R.,
McClimon, B., Jordan, M.B., Bleesing, J.J.,
Zhang, K. & Filipovich, A.H. (2010) XIAP defi-
ciency: a unique primary immunodeficiency best
classified as X-linked familial hemophagocytic
lymphohistiocytosis and not as X-linked lym-
phoproliferative disease. Blood, 116, 1079–82.
Meeths, M., Chiang, S.C.C., L€ofstedt, A., M€uller,
M.L., Tesi, B., Henter, J.I. & Bryceson, Y.T.
(2014) Pathophysiology and spectrum of dis-
eases caused by defects in lymphocyte cytotoxic-
ity. Experimental Cell Research, 325, 10–17.
Nagasawa, M., Yi, Z., Imashuku, S., Nonoyama, S.,
Ogawa, K., Okumura, K. & Mizutani, S. (2008)
Soluble TWEAK is markedly elevated in
hemophagocytic lymphohistiocytosis. American
Journal of Hematology, 83, 222–5.
Nakamura, L., Bertling, A., Brodde, M.F., Zur
Stadt, U., Schulz, A.S., Ammann, S., Sandrock-
Lang, K., Beutel, K., Zieger, B. & Kehrel, B.E.
(2015) First characterization of platelet secretion
defect in patients with familial hemophagocytic
lymphohistiocytosis type 3 (FHL-3). Blood, 125,
412–4.
Ohadi, M., Lalloz, M.R., Sham, P., Zhao, J., Dear-
love, A.M., Shiach, C., Kinsey, S., Rhodes, M. &
Layton, D.M. (1999) Localization of a gene for
familial hemophagocytic lymphohistiocytosis at
chromosome 9q21.3-22 by homozygosity map-
ping. American Journal of Human Genetics, 64,
165–71.
Ohyagi, H., Onai, N., Sato, T., Yotsumoto, S., Liu,
J., Akiba, H., Yagita, H., Atarashi, K., Honda,
K., Roers, A., M€uller, W., Kurabayashi, K.,
Hosoi-Amaike, M., Takahashi, N., Hirokawa,
M., Matsushima, K., Sawada, K. & Ohteki, T.
(2013) Monocyte-derived dendritic cells perform
hemophagocytosis to fine-tune excessive
immune responses. Immunity, 39, 584–98.
Osugi, Y., Hara, J., Tagawa, S., Takai, K., Hosoi,
G., Matsuda, Y., Ohta, H., Fujisaki, H., Kobaya-
shi, M., Sakata, N., Kawa-Ha, K., Okada, S. &
Tawa, A. (1997) Cytokine production regulating
Th1 and Th2 cytokines in hemophagocytic lym-
phohistiocytosis. Blood, 89, 4100–3.
Pachlopnik Schmid, J., Ho, C.-H., Chretien, F.,
Lefebvre, J.M., Pivert, G., Kosco-Vilbois, M.,
Ferlin, W., Geissmann, F., Fischer, A. & de Saint
Basile, G. (2009) Neutralization of IFNgamma
defeats haemophagocytosis in LCMV-infected
perforin- and Rab27a-deficient mice. EMBO
Molecular Medicine, 1, 112–24.
Pagel, J., Beutel, K., Lehmberg, K., Koch, F., Maul-
Pavicic, A., Rohlfs, A.-K., Al-Jefri, A., Beier, R.,
Bomme Ousager, L., Ehlert, K., Gross-Wieltsch,
U., Jorch, N., Kremens, B., Pekrun, A., Sparber-
Sauer, M., Mejstrikova, E., Wawer, A., Ehl, S.,
zur Stadt, U. & Janka, G. (2012) Distinct muta-
tions in STXBP2 are associated with variable
clinical presentations in patients with familial
hemophagocytic lymphohistiocytosis type 5
(FHL5). Blood, 119, 6016–24.
Palendira, U., Low, C., Chan, A., Hislop, A.D.,
Ho, E., Phan, T.G., Deenick, E., Cook, M.C.,
Riminton, D.S., Choo, S., Loh, R., Alvaro, F.,
Booth, C., Gaspar, H.B., Moretta, A., Khanna,
R., Rickinson, A.B. & Tangye, S.G. (2011)
Molecular pathogenesis of EBV susceptibility in
XLP as revealed by analysis of female carriers
with heterozygous expression of SAP. PLoS Biol-
ogy, 9, e1001187.
Palmblad, K., Schierbeck, H., Sundberg, E., Horne,
A.-C., Harris, H.E., Henter, J.-I., Antoine, D.J. &
Andersson, U. (2014) High systemic levels of
the cytokine-inducing HMGB1 isoform secreted
in severe macrophage activation syndrome.
Molecular Medicine, 20, 538–47.
Prencipe, G., Caiello, I., Bracaglia, C., de Min, C.
& De Benedetti, F. (2015) Neutralization of
Interferon-gamma is efficacious in a mouse
model of HLH secondary to chronic inflamma-
tion. Pediatric Rheumatology, 13, O29.
Put, K., Avau, A., Brisse, E., Mitera, T., Put, S.,
Proost, P., Bader-Meunier, B., Westhovens, R.,
Van den Eynde, B.J., Orabona, C., Fallarino, F.,
De Somer, L., Tousseyn, T., Quartier, P., Wou-
ters, C. & Matthys, P. (2015) Cytokines in sys-
temic juvenile idiopathic arthritis and
haemophagocytic lymphohistiocytosis: tipping
the balance between interleukin-18 and inter-
feron-c. Rheumatology, 54, 1507–1517.
Qian, Y., Johnson, J.A., Connor, J.A., Valencia, A.,
Barasa, N., Schubert, J., Husami, A., Kissell, D.,
Zhang, G., Weirauch, M.T., Filipovich, A.H. &
Zhang, K. (2014) The 253-kb inversion and
deep intronic mutations in UNC13D are present
in North American patients with familial
hemophagocytic lymphohistiocytosis 3. Pediatric
Blood & Cancer, 61, 1034–1040.
Qiang, Q., Zhengde, X., Chunyan, L., Zhizhuo, H.,
Junmei, X., Junhong, A., Zheng, C., Henter, J.-I.
& Kunling, S. (2012) Killer cell immunoglobu-
lin-like receptor gene polymorphisms predispose
susceptibility to Epstein-Barr virus associated
hemophagocytic lymphohistiocytosis in Chinese
children. Microbiology and Immunology, 56, 378–
84.
Ramanan, A.V. & Schneider, R. (2003) Macro-
phage activation syndrome–what’s in a name!.
The Journal of Rheumatology, 30, 2513–6.
Ramos-Casals, M., Brito-Zeron, P., Lopez-Guil-
lermo, A., Khamashta, M.A. & Bosch, X. (2014)
Adult haemophagocytic syndrome. Lancet, 383,
1503–16.
Rigante, D., Emmi, G., Fastiggi, M., Silvestri, E. &
Cantarini, L. (2015) Macrophage activation syn-
drome in the course of monogenic autoinflam-
matory disorders. Clinical Rheumatology, 34,
1333–1339.
Rood, J.E., Rao, S., Paessler, M., Kreiger, P.A.,
Chu, N., Stelekati, E., Wherry, E.J. & Behrens,
E.M. (2016) ST2 contributes to T cell hyperacti-
vation and fatal hemophagocytic lymphohistio-
cytosis in mice. Blood, 127, 426–435.
Rouphael, N.G., Talati, N.J., Vaughan, C., Cunning-
ham, K., Moreira, R. & Gould, C. (2007) Infec-
tions associated with haemophagocytic syndrome.
The Lancet. Infectious diseases, 7, 814–822.
de Saint Basile, G., Sepulveda, F.E., Maschalidi, S.
& Fischer, A. (2015) Cytotoxic granule secretion
Review
ª 2016 John Wiley & Sons Ltd, British Journal of Haematology 13
by lymphocytes and its link to immune home-
ostasis. F1000Research, 4, 930–938.
Schulert, G.S., Zhang, M., Fall, N., Husami, A.,
Kissell, D., Hanosh, A., Zhang, K., Davis, K.,
Jentzen, J.M., Napolitano, L., Siddiqui, J., Smith,
L.B., Harms, P.W., Grom, A.A. & Cron, R.Q.
(2016) Whole exome sequencing reveals muta-
tions in hemophagocytic lymphohistiocytosis
and macrophage activation syndrome linked
genes in fatal cases of H1N1 influenza. The Jour-
nal of Infectious Diseases, 213, 1180–1188.
Sepulveda, F.E., Debeurme, F., Menasche, G., Kur-
owska, M., Co^te, M., Pachlopnik Schmid, J., Fis-
cher, A. & de Saint Basile, G. (2013) Distinct
severity of HLH in both human and murine
mutants with complete loss of cytotoxic effector
PRF1, RAB27A, and STX11. Blood, 121, 595–
603.
Sepulveda, F.E., Maschalidi, S., Vosshenrich,
C.A.J., Garrigue, A., Kurowska, M., Menasche,
G., Fischer, A., Di Santo, J.P. & de Saint Basile,
G. (2015) A novel immunoregulatory role for
NK-cell cytotoxicity in protection from HLH-
like immunopathology in mice. Blood, 125,
1427–34.
Sepulveda, F.E., Garrigue, A., Maschalidi, S.,
Garfa-Traore, M., Menasche, G., Fischer, A. &
de Saint Basile, G. (2016) Polygenic mutations
in the cytotoxicity pathway increase susceptibil-
ity to develop HLH immunopathology in mice.
Blood. doi:10.1182/blood-2015-12-688960
Sieni, E., Cetica, V., Hackmann, Y., Coniglio,
M.L., Da Ros, M., Ciambotti, B., Pende, D.,
Griffiths, G. & Arico, M. (2014) Familial
hemophagocytic lymphohistiocytosis: when rare
diseases shed light on immune system function-
ing. Frontiers in Immunology, 5, 1–19.
Spessott, W.A., Sanmillan, M.L., McCormick,
M.E., Patel, N., Villanueva, J., Zhang, K.,
Nichols, K.E. & Giraudo, C.G. (2015)
Hemophagocytic lymphohistiocytosis caused by
dominant-negative mutations in STXBP2 that
inhibit SNARE-mediated membrane fusion.
Blood, 125, 1566–77.
Stepensky, P., Bartram, J., Barth, T.F., Lehmberg,
K., Walther, P., Amann, K., Philips, A.D., Berin-
ger, O., Zur Stadt, U., Schulz, A., Amrolia, P.,
Weintraub, M., Debatin, K., Hoenig, M. &
Posovszky, C. (2013) Persistent Defective Mem-
brane Trafficking in Epithelial Cells of Patients
With Familial Hemophagocytic Lymphohistiocy-
tosis Type 5 Due to STXBP2/MUNC18-2 Muta-
tions. Pediatric Blood & Cancer, 60, 1215–22.
Stepp, S.E., Dufourcq-Lagelouse, R., Le Deist, F.,
Bhawan, S., Certain, S., Mathew, P.A., Henter,
J.I., Bennett, M., Fischer, A., de Saint Basile, G.
& Kumar, V. (1999) Perforin gene defects in
familial hemophagocytic lymphohistiocytosis.
Science, 286, 1957–9.
Strippoli, R., Carvello, F., Scianaro, R., De Pas-
quale, L., Vivarelli, M., Petrini, S., Bracci-Lau-
diero, L. & De Benedetti, F. (2012)
Amplification of the response to Toll-like recep-
tor ligands by prolonged exposure to inter-
leukin-6 in mice: implication for the
pathogenesis of macrophage activation syn-
drome. Arthritis and Rheumatism, 64, 1680–8.
Strippoli, R., Caiello, I. & De Benedetti, F. (2013)
Reaching the threshold: a multilayer pathogene-
sis of macrophage activation syndrome. The
Journal of Rheumatology, 40, 761–7.
Sumegi, J., Barnes, M.G., Nestheide, S.V., Molleran-
Lee, S., Villanueva, J., Zhang, K., Risma, K.A.,
Grom, A.A. & Filipovich, A.H. (2011) Gene
expression profiling of peripheral blood mononu-
clear cells from children with active hemophago-
cytic lymphohistiocytosis. Blood, 117, e151–60.
Tang, B.L. (2015) A unique SNARE machinery for
exocytosis of cytotoxic granules and platelets
granules. Molecular Membrane Biology, 32,
1464–5203.
Teramura, T., Tabata, Y., Yagi, T., Morimoto, A.,
Hibi, S. & Imashuku, S. (2002) Quantitative
analysis of cell-free Epstein-Barr virus genome
copy number in patients with EBV-associated
hemophagocytic lymphohistiocytosis. Leukemia
and Lymphoma, 43, 173–179.
Terrell, C.E. & Jordan, M.B. (2013) Perforin defi-
ciency impairs a critical immunoregulatory loop
involving murine CD8(+) T cells and dendritic
cells. Blood, 121, 5184–5191.
Tesi, B., Chiang, S.C.C., El-Ghoneimy, D., Hus-
sein, A.A., Langenski€old, C., Wali, R., Fadoo, Z.,
Silva, J.P., Lecumberri, R., Unal, S., Norden-
skj€old, M., Bryceson, Y.T., Henter, J.-I. &
Meeths, M. (2015a) Spectrum of atypical clinical
presentations in patients with biallelic PRF1
missense mutations. Pediatric Blood & Cancer,
62, 2094–2100.
Tesi, B., Lagerstedt-Robinson, K., Chiang, S.C.C.,
Bdira, E.Ben., Abboud, M., Belen, B., Deve-
cioglu, O., Fadoo, Z., Yeoh, A.E.J., Erichsen,
H.C., M€ott€onen, M., Akar, H.H., H€astbacka, J.,
Kaya, Z., Nunes, S., Patiroglu, T., Sabel, M.,
Saribeyoglu, E.T., Tvedt, T.H., Unal, E., Unal,
S., Unuvar, A., Meeths, M., Henter, J.-I., Nor-
denskj€old, M. & Bryceson, Y.T. (2015b) Tar-
geted high-throughput sequencing for genetic
diagnostics of hemophagocytic lymphohistiocy-
tosis. Genome Medicine, 7, 130–142.
Tesi, B., Sieni, E., Neves, C., Romano, F., Cetica,
V., Cordeiro, A.I., Chiang, S., Schlums, H.,
Galli, L., Avenali, S., Tondo, A., Canessa, C.,
Henter, J.-I., Nordenskj€old, M., Hsu, A.P., Hol-
land, S.M., Neves, J.F., Azzari, C. & Bryceson,
Y.T. (2015c) Hemophagocytic lymphohistiocyto-
sis in 2 patients with underlying IFN-c receptor
deficiency. The Journal of Allergy and Clinical
Immunology, 135, 1638–41.
Usmani, G.N., Woda, B.a. & Newburger, P.E.
(2013) Advances in understanding the patho-
genesis of HLH. British Journal of Haematology,
161, 609–622.
Vastert, S.J., van Wijk, R., D’Urbano, L.E., de
Vooght, K.M.K., de Jager, W., Ravelli, A.,
Magni-Manzoni, S., Insalaco, A., Cortis, E., van
Solinge, W.W., Prakken, B.J., Wulffraat, N.M.,
de Benedetti, F. & Kuis, W. (2010) Mutations in
the perforin gene can be linked to macrophage
activation syndrome in patients with systemic
onset juvenile idiopathic arthritis. Rheumatology,
49, 441–9.
Verbsky, J.W. & Grossman, W.J. (2006)
Hemophagocytic lymphohistiocytosis: diagnosis,
pathophysiology, treatment, and future perspec-
tives. Annals of Medicine, 38, 20–31.
Wang, Y., Wang, Z., Zhang, J., Wei, Q., Tang, R.,
Qi, J., Li, L., Ye, L., Wang, J. & Ye, L. (2014)
Genetic features of late onset primary
hemophagocytic lymphohistiocytosis in adoles-
cence or adulthood. PLoS One, 9, e107386.
Wang, Y., Ai, J., Xie, Z., Qin, Q., Wu, L., Liu, Y.,
Liu, C. & Shen, K. (2015) IL-10-592 A/C
polymorphisms is associated with EBV-HLH in
Chinese children. Hematology. doi:10.1179/
1607845415Y.0000000040
Xu, X.-J., Tang, Y.-M., Song, H., Yang, S.-L., Xu,
W.-Q., Zhao, N., Shi, S.-W., Shen, H.-P., Mao,
J.-Q., Zhang, L.-Y. & Pan, B.-H. (2012) Diag-
nostic accuracy of a specific cytokine pattern in
hemophagocytic lymphohistiocytosis in children.
The Journal of Pediatrics, 160, e1.
Yanagimachi, M., Goto, H., Miyamae, T., Kadota,
K., Imagawa, T., Mori, M., Sato, H., Yanagi-
sawa, R., Kaneko, T., Morita, S., Ishii, E. &
Yokota, S. (2011a) Association of IRF5 polymor-
phisms with susceptibility to hemophagocytic
lymphohistiocytosis in children. Journal of Clini-
cal Immunology, 31, 946–51.
Yanagimachi, M., Naruto, T., Miyamae, T., Hara,
T., Kikuchi, M., Hara, R., Imagawa, T., Mori,
M., Sato, H., Goto, H. & Yokota, S. (2011b)
Association of IRF5 polymorphisms with sus-
ceptibility to macrophage activation syndrome
in patients with juvenile idiopathic arthritis. The
Journal of Rheumatology, 38, 769–74.
Yang, X., Hoshino, A., Taga, T., Kunitsu, T., Ikeda,
Y., Yasumi, T., Yoshida, K., Wada, T., Miyake,
K., Kubota, T., Okuno, Y., Muramatsu, H., Ada-
chi, Y., Miyano, S., Ogawa, S., Kojima, S. &
Kanegane, H. (2015) A female patient with
incomplete hemophagocytic lymphohistiocytosis
caused by a heterozygous XIAP mutation associ-
ated with non-random X-chromosome inactiva-
tion skewed towards the wild-type XIAP allele.
Journal of Clinical Immunology, 35, 244–8.
Zhang, K., Biroschak, J., Glass, D.N., Thompson,
S.D., Finkel, T., Passo, M.H., Binstadt, B.A., Fili-
povich, A. & Grom, A.A. (2008a) Macrophage
activation syndrome in patients with systemic
juvenile idiopathic arthritis is associated with
MUNC13-4 polymorphisms. Arthritis and
Rheumatism, 58, 2892–6.
Zhang, S., Ma, D., Wang, X., Celkan, T., Norden-
skj€old, M., Henter, J.I., Fadeel, B. & Zheng, C.
(2008b) Syntaxin-11 is expressed in primary
human monocytes/macrophages and acts as a
negative regulator of macrophage engulfment
of apoptotic cells and IgG-opsonized target
cells. British Journal of Haematology, 142, 469–
479.
Zhang, K., Jordan, M.B., Marsh, R.A., Johnson,
J.A., Kissell, D., Meller, J., Villanueva, J., Risma,
K.A., Wei, Q., Klein, P.S. & Filipovich, A.H.
(2011) Hypomorphic mutations in PRF1,
Review
14 ª 2016 John Wiley & Sons Ltd, British Journal of Haematology
MUNC13-4, and STXBP2 are associated with
adult-onset familial HLH. Blood, 118, 5794–
5798.
Zhang, K., Chandrakasan, S., Chapman, H., Valen-
cia, C.A., Husami, A., Kissell, D., Johnson, J.A.
& Filipovich, A.H. (2014a) Synergistic defects of
different molecules in the cytotoxic pathway
lead to clinical familial hemophagocytic lympho-
histiocytosis. Blood, 124, 1331–4.
Zhang, M., Behrens, E.M., Atkinson, T.P., Shako-
ory, B., Grom, A.A. & Cron, R.Q. (2014b)
Genetic defects in cytolysis in macrophage acti-
vation syndrome. Current Rheumatology Reports,
16, 439–446.
Zhang, M., Bracaglia, C., Prencipe, G., Bemrich-
Stolz, C.J., Beukelman, T., Dimmitt, R.A., Cha-
tham, W.W., Zhang, K., Li, H., Walter, M.R.,
De Benedetti, F., Grom, A.A. & Cron, R.Q.
(2016) A heterozygous RAB27A mutation asso-
ciated with delayed cytolytic granule polarization
and hemophagocytic lymphohistiocytosis. The
Journal of Immunology, 196, 2492–503.
Zoller, E.E., Lykens, J.E., Terrell, C.E., Aliberti, J.,
Filipovich, A.H., Henson, P.M. & Jordan, M.B.
(2011) Hemophagocytosis causes a consumptive
anemia of inflammation. The Journal of Experi-
mental Medicine, 208, 1203–1214.
ª 2016 John Wiley & Sons Ltd, British Journal of Haematology 15
Review
